Experts has a new look! Let us know what you think of the updates.

Provide feedback

Scholarly Works

Randomized, double-blind, placebo-controlled trial...

Journal article

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

Abstract

PURPOSE We designed and conducted a randomized, double-blind, placebo-controlled trial to compare the response rates and survival of patients with metastatic melanoma who received carmustine (BCNU), dacarbazine (DTIC), and cisplatin with tamoxifen, or the same chemotherapy with placebo. PATIENTS AND METHODS Eligible patients with metastatic melanoma received either BCNU 150 mg/m2 intravenously (i.v.) on day 1, DTIC 220 mg/m2 i.v. daily on days …

Authors

Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK

Journal

Journal of Clinical Oncology, Vol. 14, No. 7, pp. 2083–2090

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

July 1996

DOI

10.1200/jco.1996.14.7.2083

ISSN

0732-183X

Associated Experts

James Rusthoven

Professor Emeritus, Faculty of Health Sciences

Labels

Medical Subject Headings (MeSH)

Adult Aged Antineoplastic Combined Chemotherapy Protocols Carmustine Cisplatin Dacarbazine Disease-Free Survival Double-Blind Method Female Humans Male Melanoma Middle Aged Skin Neoplasms Survival Rate Tamoxifen

Fields of Research (FoR)

3211 Oncology and carcinogenesis

View published work (Non-McMaster Users)

View published work (McMaster Users)